CA2615468C - Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications - Google Patents

Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications Download PDF

Info

Publication number
CA2615468C
CA2615468C CA2615468A CA2615468A CA2615468C CA 2615468 C CA2615468 C CA 2615468C CA 2615468 A CA2615468 A CA 2615468A CA 2615468 A CA2615468 A CA 2615468A CA 2615468 C CA2615468 C CA 2615468C
Authority
CA
Canada
Prior art keywords
pvp2
ibdv
region
protein
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2615468A
Other languages
English (en)
French (fr)
Other versions
CA2615468A1 (en
Inventor
Jose Francisco Rodriguez Aguirre
Jose Ruiz Caston
Irene Saugar Gomez
Ana Maria Ona Blanco
Juan Ramon Rodriguez Fernandez-Alba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIONOSTRA SL
Consejo Superior de Investigaciones Científicas
Original Assignee
BIONOSTRA SL
Consejo Superior de Investigaciones Científicas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIONOSTRA SL, Consejo Superior de Investigaciones Científicas filed Critical BIONOSTRA SL
Publication of CA2615468A1 publication Critical patent/CA2615468A1/en
Application granted granted Critical
Publication of CA2615468C publication Critical patent/CA2615468C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2615468A 2005-07-15 2006-07-14 Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications Expired - Lifetime CA2615468C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200501733A ES2310062B1 (es) 2005-07-15 2005-07-15 Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
ESP200501733 2005-07-15
PCT/EP2006/006915 WO2007009673A1 (en) 2005-07-15 2006-07-14 Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications

Publications (2)

Publication Number Publication Date
CA2615468A1 CA2615468A1 (en) 2007-01-25
CA2615468C true CA2615468C (en) 2015-04-14

Family

ID=37662111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2615468A Expired - Lifetime CA2615468C (en) 2005-07-15 2006-07-14 Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications

Country Status (9)

Country Link
US (1) US7476387B2 (enExample)
EP (1) EP1904626B1 (enExample)
JP (1) JP5713533B2 (enExample)
CN (1) CN101278043A (enExample)
AT (1) ATE516345T1 (enExample)
AU (1) AU2006271978B2 (enExample)
CA (1) CA2615468C (enExample)
ES (2) ES2310062B1 (enExample)
WO (1) WO2007009673A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2093281A1 (en) * 2008-02-19 2009-08-26 Kapsid Link, S.L. Protein nanocarriers, process for obtaining them and applications
US8784827B2 (en) * 2008-05-09 2014-07-22 Chimera Pharma S.L.U Chimeric fusion proteins and virus like particles from Birnavirus VP2
AU2010316998B2 (en) * 2009-11-06 2014-05-22 Chimera Pharma, S.L.U. Vaccines for the treatment of neoplasias from viral capsids of birnavirus containing antigens of the human papillomavirus
WO2011054995A2 (es) 2009-11-06 2011-05-12 Chimera Pharma, S. L. U. VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE
AU2012360168C1 (en) 2011-11-03 2017-09-28 Sentinext Therapeutics Sdn Bhd Vaccines directed against human Enteroviruses
US10086062B2 (en) 2012-07-05 2018-10-02 Ohio State Innovation Foundation Infectious pancreatic necrosis virus (IPNV) vaccine compositions
WO2014008475A2 (en) 2012-07-05 2014-01-09 The Ohio State University Compositions and methods related to viral vaccines
EP3089755A1 (en) * 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
CN107034198B (zh) 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
CN108624611A (zh) * 2018-05-15 2018-10-09 武汉科前生物股份有限公司 传染性法氏囊病毒病毒样颗粒的制备及其应用
WO2023062182A1 (en) * 2021-10-15 2023-04-20 Aquilón Cyl, S.L. Vaccine compositions against bovine viral diarrhea virus
CN114058524A (zh) * 2021-10-28 2022-02-18 复旦大学 一种法氏囊亚病毒颗粒疫苗及其制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3585578D1 (de) 1984-06-18 1992-04-16 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
US5614409A (en) 1989-05-30 1997-03-25 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
US5641490A (en) 1991-03-07 1997-06-24 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
WO1992022575A1 (en) 1991-06-19 1992-12-23 Sri International M-protein peptides of influenza virus as antiviral agents
CA2110505A1 (en) 1991-07-26 1993-02-18 Enzo Paoletti Infectious bursal disease virus recombinant poxvirus vaccine
US5658572A (en) 1991-07-26 1997-08-19 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
JPH05194597A (ja) 1991-12-20 1993-08-03 Nippon Seibutsu Kagaku Kenkyusho 防御抗原性を有する伝染性ファブリキウス嚢病ウイルス（ｉｂｄｖ）の粒子製造法
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
ES2282998T3 (es) 1996-01-02 2007-10-16 Institut Pasteur Pseudo-particularmente viricas recombinadas y aplicaciomnes vacunales y antitumorales.
US5871744A (en) 1996-09-05 1999-02-16 University Of Maryland-Biotechnology Inst. Method for generating birnavirus from synthetic RNA transcripts
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
EP0861665A1 (en) 1997-02-03 1998-09-02 Dimminaco Ag/Sa/Ltd. Infectious bursitis vaccine
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
CA2238659C (en) 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
EP0887412B1 (en) 1997-05-26 2003-10-15 Akzo Nobel N.V. Recombinant birnavirus vaccine
US6596280B1 (en) 1997-07-31 2003-07-22 University Of Maryland Biotechnology Institute Method for generating birnavirus from synthetic RNA transcripts
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6231868B1 (en) 1997-09-30 2001-05-15 University Of Maryland-Biotechnology Institute Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
US6406843B1 (en) 1998-02-27 2002-06-18 University Of Arkansas Poultry virus isolates and method
US6274147B1 (en) 1998-03-31 2001-08-14 University Of Maryland-Biotechnology Institute Method for generating nonpathogenic infectious pancreatic necrosis virus (IPNV) from synthetic RNA transcripts
US6114112A (en) 1998-05-21 2000-09-05 The Ohio State University Method of making immunogenic compositions for infectious bursal disease virus
WO2000023955A1 (en) * 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
HUP9802974A1 (hu) 1998-12-19 2000-09-28 Mezőgazdasági Biotechnológiai Kutatóközpont Fertőző bursitis elleni DNS-vakcina
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6528063B2 (en) * 1999-01-04 2003-03-04 Rahan Meristem Recombinant vaccines against IBDV
EP1069187A1 (en) 1999-07-14 2001-01-17 Stichting Dienst Landbouwkundig Onderzoek Mosaic Infectious Bursal Disease Virus vaccines
FR2806087B1 (fr) 2000-03-07 2002-10-18 Agronomique Inst Nat Rech Particules pseudovirales de rotavirus et leur utilisation pour vectoriser des proteines ou des acides nucleiques
AU5533601A (en) 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
US20020165176A1 (en) 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
EP1278542A2 (en) * 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
AU2000252449A1 (en) 2000-06-19 2002-01-02 Rahan Meristem Recombinant vaccines against infectious bursal disease virus
ATE376059T1 (de) 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
DK2270171T5 (da) * 2000-10-02 2013-11-18 Id Biomedical Corp Quebec Haemophilus influenzae-antigener og tilsvarende DNA-fragmenter
US7449188B2 (en) 2001-01-18 2008-11-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Recombinant oligometric protein complexes with enhanced immunogenic potential
FR2824327B1 (fr) * 2001-05-02 2003-07-11 Agronomique Inst Nat Rech Particules pseudovirales de birnavirus
WO2002096940A2 (en) 2001-05-31 2002-12-05 Id-Lelystad, Institut Voor Dierhouderij En Diergezondheid B.V. Attenuated very virulent infectious bursal disease virus
CA2457349A1 (en) 2001-08-10 2003-02-20 University Of Maryland Biotechnology Institute Sub-unit vaccine for infectious pancreatic necrosis virus
AUPR721101A0 (en) * 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
EP1472353B1 (en) * 2002-02-11 2012-02-01 ID Biomedical Corporation Group b streptococcus antigen
WO2003074552A1 (en) 2002-03-01 2003-09-12 Akzo Nobel N.V. An infectious bursal disease virus variant
US7407807B2 (en) 2002-05-17 2008-08-05 University Of Cape Town Chimaeric human papillomavirus 16 I1 virus like particles and a method for preparing the particles
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
US20060121468A1 (en) 2002-06-26 2006-06-08 Allnutt F C T Viruses and virus-like particles for multiple antigen and target display
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
EP1545600A4 (en) 2002-09-16 2006-07-12 Advanced Bionutrition Corp PROTEIN AND PEPTIDE EXPRESSION FOR PASSIVE IMMUNITY
EP1603590A4 (en) 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
ES2217967B1 (es) 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
ES2593082T3 (es) 2003-05-28 2016-12-05 Wisconsin Alumni Research Foundation Virus de la gripe recombinantes a título elevado para vacunas y terapia génica
AU2004255470B2 (en) 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
ES2307346B1 (es) 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2242542B1 (es) 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
RS51665B (sr) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
NZ554387A (en) 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
US7244432B2 (en) 2004-12-08 2007-07-17 University Of Maryland Biotechnology Institute Infectious bursal disease virus (IBDV) variant from Georgia

Also Published As

Publication number Publication date
CA2615468A1 (en) 2007-01-25
ES2371833T3 (es) 2012-01-10
EP1904626A1 (en) 2008-04-02
US7476387B2 (en) 2009-01-13
ES2310062B1 (es) 2009-11-13
AU2006271978B2 (en) 2012-08-02
WO2007009673A1 (en) 2007-01-25
ES2310062A1 (es) 2008-12-16
CN101278043A (zh) 2008-10-01
EP1904626B1 (en) 2011-07-13
JP5713533B2 (ja) 2015-05-07
AU2006271978A1 (en) 2007-01-25
ATE516345T1 (de) 2011-07-15
US20070015243A1 (en) 2007-01-18
JP2009501012A (ja) 2009-01-15

Similar Documents

Publication Publication Date Title
CN113416236B (zh) 猪圆环病毒3型病毒样颗粒及其制备方法与应用
EP1904626B1 (en) Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications
EP1706486B1 (en) Chimeric empty capsids of the infectious bursal disease virus (ibdv), obtainment process and applications
ES2242542B1 (es) Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
EP2093281A1 (en) Protein nanocarriers, process for obtaining them and applications
US6187319B1 (en) Cross-protective rotavirus vaccine
EP1706485B1 (en) EMPTY CAPSIDS (VLPs(-VP4)) OF THE INFECTIOUS BURSAL DISEASE VIRUS (IBDV), OBTAINMENT PROCESS AND APPLICATIONS
CN121752290A (zh) Dev作载体的禽流感h9疫苗
JP2022549257A (ja) ファージｔ５由来ナノ粒子の作製及び機能化並びに治療用途
EP4495247A1 (en) Virus-like particle containing capsid proteins connected by linker
US20070010015A1 (en) Complete empty viral particles of infectious bursal disease virus (ibdv), production method thereof and applications of same
WO2025201387A1 (en) A recombinant serotype 1 marek's disease virus
CN120192991A (zh) 一种通过大肠杆菌制备o型口蹄疫病毒多表位病毒样颗粒的方法及其产品和应用
US20040234949A1 (en) Icosahedral superstructures of vp2 of infectious bursitis virus (ibdv) and the applications thereof
TWI233947B (en) Method for preparing IBDV infectious sub-unit and vaccine and diagnostic reagent made therefrom
VP et al. ABBS 2005, 37 (10): Vaccination against Very Virulent Infectious Bursal Disease Virus Using Recombinant T4 Bacteriophage Displaying Viral Protein VP2
TW200525031A (en) Method for producing virus-like particles of Infectious Bursal Disease viruses by E. coli and its application in subunit vaccine

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707